The following table sets forth the outstanding shares of common stock equivalents, presented based on amounts outstanding at each period end, which were excluded from the calculation of diluted net loss per share allocable to common stockholders for the periods indicated because including them would have been anti-dilutive:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Series A Preferred Stock		—		1,002,805		—		1,002,805
Series B Preferred Stock		—		4,069,102		—		4,069,102
Series C Preferred Stock		—		6,540,022		—		6,540,022
Series D Preferred Stock		—		12,669,755		—		12,669,755
Series E Preferred Stock		—		15,128,745		—		15,128,745
Common stock warrants		—		24,152		—		24,152
Outstanding stock options		15,269,049		8,607,087		15,269,049		8,607,087
Total		15,269,049		48,041,668		15,269,049		48,041,668

The amounts of outstanding stock options in the table above for the three and six months ended June 30, 2026 and 2025 exclude 419,506 potentially dilutive securities as these outstanding stock options relate to contingently issuable shares for which the market condition was not satisfied as of the respective period end.